Evidence map›Paper›PMID 35094663›Full record

ArticleRedox report : communications in free radical research2022

The emerging role of irisin in experimentally induced arthritis: a recent update involving HMGB1/MCP1/Chitotriosidase I-mediated necroptosis.

Rowida Raafat Ibrahim, Noha M Shafik, Rasha Osama El-Esawy, Mervat H El-Sakaa, Heba M Arakeeb, Radwa Mahmoud El-Sharaby, Dina Adam Ali, Omnia Safwat El-Deeb, Sara Ragab Abd El-Khalik

Open access · goldAbstract read
In one paragraph

Article in Redox report : communications in free radical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Frontier research on mechanisms of bone destruction in rheumatoid arthritis.Frontiers in cell and developmental biology · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Programmed Cell Death in Rheumatoid Arthritis.Journal of inflammation research · 2025
    Review
  8. Review
  9. Peptide BG From Bitter Gourd (Mediators of inflammation · 2024
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Role of irisin in bone diseases.Frontiers in endocrinology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Rowida Raafat IbrahimMedical Biochemistry & Molecular Biology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.ORCID 0000-0002-6500-8156
Noha M ShafikMedical Biochemistry & Molecular Biology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Rasha Osama El-EsawyPharmacology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Mervat H El-SakaaPhysiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Heba M ArakeebAnatomy & Embryology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Radwa Mahmoud El-SharabyClinical pathology department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Dina Adam AliClinical pathology department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Omnia Safwat El-DeebMedical Biochemistry & Molecular Biology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Sara Ragab Abd El-KhalikMedical Biochemistry & Molecular Biology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Tanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesNecroptosis is a tightly adjusted inflammatory necrotizing cell death signaling pathway that participates in pathogenesis of discrete diseases as rheumatoid arthritis (RA). Irisin is a myokine with immuno-modulatory effect. Evaluation of irisin efficiency as a novel therapeutic agent in experimentally induced RA via modulating immuno-inflammatory, necroptotic molecular and biochemical signaling pathways.

methodsRA was induced in 30 female Wister albino rats by a single subcutaneous injection of collagen-II with incomplete Freund's adjuvant (CII-IFA) followed by booster immunization dose 10 days later. After 14 days of the injection, arthritis chronic phase was precipitated. 15 rats were treated by S.C irisin injection daily for 4 weeks. Joint tissue homogenate RIPK-3, MLKL, HMGB1, MCP1, IL-6, CHIT1, MDA, and PN levels were assessed calorimetrically. However, TNF-α mRNA expression level was evaluated by the qrt-PCR technique.

resultsThe results showed that irisin significantly decreases the level of all assessed biochemical parameters, except MDA, which was significantly increased in comparison with the correspondent values in the arthritic group with no treatment (ttt).

conclusionsIrisin exhibits therapeutic anti-inflammatory and antioxidant effects via modulating immuno-inflammatory, necroptotic molecular, and biochemical signaling pathways in experimentally induced RA in rats. ABBREVIATIONS: RA: rheumatoid arthritis; RIPK3: receptor-interacting protein kinase 1; MLKL: mixed lineage kinase domain-like protein; HMGB1: High-mobility group protein box 1; MCP1: Monocyte chemoattractant protein 1; IL-6: Interleukin 6; CHIT1: Chitotriosidase; MDA: Malondialdehyde; PN: Peroxynitrite; TNF-α: Tumor Necrosis Factor; qrt-PCR: quantitative real-time reverse transcription PCR; CII-IFA: collagen-II with incomplete Freund's adjuvant; ttt: treatmentNote:

Indexed as

Arthritis, RheumatoidHMGB1 ProteinAnimalsChemokine CCL2FemaleHexosaminidasesNecroptosisRatsRats, WistarChemokine CCL2chitotriosidaseHbp1 protein, ratHexosaminidasesHMGB1 ProteinArthritis‌Chitotriosidase-1high-mobility group box 1IrisinMonocyte chemoattractant protein 1necroptosisRIPK1/3

Identifiers

PMID35094663
PMCPMC8803109
OpenAlexW4210726457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.